Navigation Links
Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Date:5/12/2008

ANN ARBOR, Mich., May 12 /PRNewswire/ -- Velcura Therapeutics, Inc. announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis (RA) and other bone diseases. In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss. Taken together, these characteristics strongly suggest this drug may be an important therapy for RA patients.

"The successful completion of the first studies in healthy human volunteers is an important milestone in developing VEL-0230 as a therapy," said Michael W. Long, PhD, President and Chief Executive Officer of Velcura. "While we are still analyzing and tabulating the data, our preliminary conclusions are that the drug is safe and well-tolerated over a range of doses."

"During this initial safety study in humans, the drug caused a rapid (within 15 minutes) and marked (80%) reduction in CTx levels, a biomarker of bone resorption. Our next step is to evaluate the drug for efficacy in RA patients," said Dr. Long who added, "We plan to move into multiple clinical studies as rapidly as possible."

VEL-0230 is being studied as an orally available molecule that promotes bone formation, inhibits bone loss and reduces inflammation. If successful in RA patients Velcura Therapeutics plans to study it as a treatment for other bone disorders, such as bone loss related to multiple myeloma, bone metastases, and osteoporosis.

About Velcura Therapeutics, Inc.

Velcura Therapeutics, Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, therapies that restore the balance between bone building and bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. More information is at http://www.velcura.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
2. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
10. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. ... a federal institution supporting research in Germany ... and patient treatments at the University Clinic Heidelberg as ... The MRIdian Linac program will be headed by ... also heads radiation oncology at the German Cancer Research ...
(Date:1/19/2017)...   Science Exchange , the leading marketplace ... the first five replication studies from the ... in eLife today. Despite intense scrutiny around reproducibility ... evaluation of reproducibility rates that may identify specific ... assessments of reproducibility, the results of this project ...
(Date:1/19/2017)... New Review of Safinamide ... Symptoms and Motor Complications in Mid- to Late-stage ... ... C Warren Olanow ... 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story of love, ... who lives in Lafayette, Indiana where she works in a daycare and looks for ... , Published by Christian Faith Publishing, Sara Seymour’s new book is an adventure of ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children ... the simple and achievable answer. “The Land of More and More” is the creation ... in Angola, Indiana where he works with the children’s ministry department. , Michael ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... an On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician ... on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The ...
(Date:1/19/2017)... R.I. (PRWEB) , ... January 19, 2017 , ... With the cold weather here, many ... , Snow blowers are efficient when clearing large amounts of snow, but they can be ... from the U.S. Consumer Product Safety Commission for the proper use of snow blowers:, ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media ... American Heart Association (AHA) to produce a three-part video series that uses humor to ... part of the launch of AHA’s Healthy For Good™ movement, which is designed to ...
Breaking Medicine News(10 mins):